Natera Inc Q2 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst : So first up on women's health, you mentioned that ACOG had prenatal meetings scheduled for June and September. I believe expanded carrier screening and microdeletions were on the agenda for that June meeting. So can you tell us if you have any information regarding how that meeting went? And then when -- how quickly could we see ACOG endorse 22q? Could it come right after the September meeting or just updated time line expectations there?

Question: Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst : Great. And then a follow-up here, just shifting over to oncology. Can you give us an update on your latest conversations with private payers? I understand you have Blue Cross Blue Shield of California on that pan-cancer assay, which is a positive. But how are those conversations evolving, especially ahead of some potential updates from the NCCN guidelines? And then also, I know that American Cancer Society is still trying to push in a law that commercial payers should offer the same Medicare testing. So can you just walk us through your latest expectations there? Really, what could that mean for the Signatera business?